Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OssiFi sclerostin inhibitor
- Development stage
- Preclinical
- Lead developer
- OssiFi
- Modality
- Small Molecules
01
Overview
OssiFi Therapeutics is developing a program of small molecule inhibitors targeting sclerostin, a secreted glycoprotein that acts as a potent negative regulator of bone formation. Sclerostin, encoded by the SOST gene, inhibits the Wnt/β-catenin signaling pathway in osteoblasts by binding to the LRP5/6 co-receptors, thereby suppressing bone mineral density accrual. By antagonizing sclerostin, OssiFi's small molecule candidates aim to stimulate osteoblast activity and promote bone growth. The company is specifically investigating these inhibitors for therapeutic applications in neurogenic low back pain, fracture repair acceleration, and fracture prevention. This small-molecule approach is intended to offer a potentially more convenient or differentiated alternative to existing injectable monoclonal antibody therapies that target the same pathway.
- Other names
- OssiFi sclerostin small molecule inhibitor
02
Targets
SOST (Sclerostin)
Beyond the preview
Go deeper on OssiFi sclerostin inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OssiFi sclerostin inhibitor.